Mesenchymal stem cells targeting the GVHD

Science in China, Series C: Life Sciences

Volumn 52, Issue 7, 2009, Pages 603-609

  Wang, Liang ^a   Zhao, Robert ChunHua ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Graft versus host disease (GVHD); Mesenchymal stem cells (MSCs); Treatment

Indexed keywords

CORTICOSTEROID;

BIOLOGICAL MODEL; DISEASE COURSE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELL TRANSPLANTATION; METHODOLOGY; MULTICENTER STUDY; PATHOPHYSIOLOGY; REVIEW; T LYMPHOCYTE;

ADRENAL CORTEX HORMONES; DISEASE PROGRESSION; GRAFT VS HOST DISEASE; HUMANS; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MODELS, BIOLOGICAL; MULTICENTER STUDIES AS TOPIC; T-LYMPHOCYTES;

EID: 70350054436     PISSN: 10069305     EISSN: 18622798     Source Type: Journal    
DOI: 10.1007/s11427-009-0091-7     Document Type: Review

References (56)

1. Lorenz E, Uphoff D, Reid T R, et al. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst, 1951, 12: 197-201.
2. van Bekkum D W, de Vries M J. The production of radiation chimaeras. In: Radiation Chimaeras. London, United Kingdom: Logos Press Limited, 1967. 20-78.
3. Billingham R E. The biology of graft-versus-host reactions. In: The Harvey Lectures. New York: Academic Press, 1966. 21-78.
4. Deeg H J. How I treat refractory acute GVHD. Blood, 2007, 109: 4119-4126.
5. Larghero J, Vija L, Lecourt S, et al. Mesenchymal stem cells and immunomodulation: Toward new immunosuppressive strategies for the treatment of autoimmune diseases? Rev Med Interne, 2009, 30: 287-299.
6. Aggarwal S, Pittenger M F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 2005, 105: 1815-1822.
7. Le Blanc K, Ringdén O. Immunomodulation by mesenchymal stem cells and clinical experience. J InternMed, 2007, 262: 509-525.
8. Müller I, Kordowich S, Holzwarth C, et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis, 2008, 40: 25-32.
9. Hill G R, Ferrara J L M. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000, 95: 2754-2759.
10. Ball L M, Egeler R M. EBMT Paediatric Working Party. Acute GvHD: Pathogenesis and classification. Bone Marrow Transplant, 2008, 41: S58-64.
11. David A Jacobsohn, Georgia B Vogelsang. Acute graft versus host disease. Orphanet J Rare Dis, 2007, 2: 35.
12. Messina C, Faraci M, de Fazio V, et al. Prevention and treatment of acute GvHD. Bone Marrow Transplant, 2008, 41: S65-70.
13. MacMillan M L, Weisdorf D J, Wagner J E. Response of 443 patients to steroids as primary therapy for acute GvHD: Comparison of grading system. Biol Blood Marrow Transplant, 2002, 47: 387-394.
14. van Lint M T, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylpredniso-lone: A multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood, 1998, 92: 2288-2293.
15. Cragg L, Blazar B R, Defor T, et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant, 2000, 6: 441-447.
16. van Lint M T, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone: Significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood, 2006, 107: 4177-4181.
17. Antin J H, Chen A R, Couriel D R, et al. Novel approaches to the therapy of steroid resistant acute graft versus host disease. Biol Blood Marrow Transplant, 2004, 10: 655-668.
18. Antin J H. Approaches to graft-vs-host disease. Paediatr Transplant, 2005, 9: 71-75.
19. Doney K, Martin P, Storb R, et al. A randomized trial of antihuman thymocyte globulin versus murine monoclonal antihuman T-cell antibodies as immunosuppressive therapy for aplastic anemia. Exp Hematol, 1985, 13: 520-524.
20. Curtis R E, Travis L B, Rowlings P A, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood, 1999, 94: 2208-2216.
21. Deeg H J, Blazar B R, Bolwell B J, et al. Treatment of steroid-refractory acute graft-verus-host-disease with anti-CD147 monoclonal antibody ABX-CBL. Blood, 2001, 98: 2052-2058.
22. Carpenter P A, Appelbaum F R, Corey L, et al. A humanized non-FcR-bindinganti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood, 2002, 99: 2712-2719.
23. Jacobsohn D A, Vogelsang G B. Novel pharmacotherapeutic approaches to prevention and treatment of GvHD. Drugs, 2001, 62: 879-889.
24. Benito A I, Furlong T, Martin P J, et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation, 2001, 72: 1924-1929.
25. Bolanos-Meade J, Jacobsohn D A, Margolis J, et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol, 2005, 20: 2661-2668.
26. Tyndall A, Uccelli A. Multipotent mesenchymal stromal cells for autoimmune diseases: Teaching new dogs old tricks. Bone Marrow Transplant, 2009, 43: 821-828.
27. Nauta A J, Fibbe W E. Immunomodulatory properties of mesenchymal stromal cells. Blood, 2007, 110: 3499-506.
28. Gonzalo-Daganzo R, Regidor C, Martín-Donaire T, et al. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults. Cytotherapy, 2009, 11: 278-288.
29. Noort W A, Kruisselbrink A B, in't Anker P S, et al. Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol, 2002, 30: 870-878.
30. Klyushnenkova E, Mosca J D, Zernetkina V, et al. T cell responses to allogeneic human mesenchymal stem cells: Immunogenicity, tolerance, and suppression. J Biomed Sci, 2005, 12: 47-57.
31. + regulatory T cells. Stem Cells, 2008, 26: 212-222.
32. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med, 2003, 9: 1144-1150.
33. Wolf D, Wolf A M, Fong D, et al. Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation, 2007, 83: 1107-1113.
34. Le Blanc K, Tammik C, Rosendahl K, et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol, 2003, 31: 890-896.
35. Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol, 2003, 57: 11-20.
36. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol, 2002, 30: 42-48.
37. von Bonin M, Stölzel F, Goedecke A, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant, 2009, 43: 245-251.
38. Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood, 2005, 106: 1755-1761.
39. Glennie S, Soeiro I, Dyson P J, et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood, 2005, 105: 2821-2827.
40. Le Blanc K, Rasmusson I, Gotherstrom C, et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol, 2004, 60: 307-315.
41. Bacigalupo A, Valle M, Podesta M, et al. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp Hematol, 2005, 33: 819-827.
42. Han Q, Sun Z, Liu L, et al. Impairment in immuno-modulatory function of Flk1(+)CD31(-)CD34(-) MSCss from MDS-RA patients. Leuk Res, 2007, 31: 1469-1478.
43. English K, Barry F P, Mahon B P. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett, 2008, 115: 50-58.
44. - T cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2004, 12: 666-669.
45. Jiang X X, Zhang Y, Liu B, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood, 2005, 105: 4120-4126.
46. +-derived and monocyte-derived dendritic cells. J Immunol, 2006, 177: 2080-2087.
47. Zhang B, Liu R, Shi D, et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2 dependent regulatory dendritic cell population. Blood, 2009, 113: 46-57.
48. + cells. Stem Cells Dev, 2007, 16: 719-731.
49. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood, 2006, 107: 367-372.
50. Sotiropoulou P A, Perez S A, Gritzapis A D, et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells, 2006, 24: 74-85.
51. Spaggiari G M, Capobianco A, Becchetti S, et al. Mesenchymal stem cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing MSCss, whereas MSCss can inhibit IL-2-induced NK-cell proliferation. Blood, 2006, 107: 1484-1490.
52. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet, 2008, 371: 1579-1586.
53. von Bonin M, Stölzel F, Goedecke A, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Biol Bone Marrow Transplant, 2008, 43: 1-7.
54. Fang B, Song Y, Liao L, et al. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc, 2007, 39: 3358-3362.
55. Graul A I. Promoting, improving and accelerating the drug development and approval processes. Drug News Perspect, 2008, 22: 30-38.
56. Osiris Therapeutics, Inc. Osiris therapeutics reports positive Phase II results using PROCHYMAL(TM) for the treatment of acute graft vs. host disease. BALTIMORE, Nov 09, 2006 (BUSINESS WIRE) - Osiris Therapeutics, Inc.